Apogee Therapeutics, Inc. (NASDAQ:APGE Free Report) Equities research analysts at Wedbush cut their FY2023 EPS estimates for shares of Apogee Therapeutics in a report released on...
Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE Get Free Report) have earned an average rating of Buy from the six ratings firms that are covering the firm, MarketBeat reports...
Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial PK and safety data from healthy volunteers expected...
SAN FRANCISCO and WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
Apogee Therapeutics, Inc. (NASDAQ:APGE Get Free Report)s share price hit a new 52-week low on Friday . The stock traded as low as $14.73 and last traded at $14.80, with a volume of...
Apogee Therapeutics, Inc. (NASDAQ:APGE Get Free Report) has been assigned a consensus rating of Buy from the six brokerages that are covering the firm, MarketBeat reports. Six...
Apogee Therapeutics, Inc. (NASDAQ:APGE Get Free Report) shares saw an uptick in trading volume on Monday . 256,093 shares traded hands during mid-day trading, a decline of 14% from the...
SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
Apogee Therapeutics, Inc. (NASDAQ:APGE Get Free Report) shares dropped 3.7% during trading on Wednesday . The company traded as low as $20.03 and last traded at $20.03. Approximately 1,471...